Uso de psicofármacos para síntomas neuropsiquiátricos en pacientes hospitalizados con COVID-19

Autores/as

DOI:

https://doi.org/10.24265/horizmed.2021.v21n2.13

Palabras clave:

Psicotrópicos; Hospitalización; Coronavirus; COVID-19

Resumen

Actualmente estamos viviendo una crisis mundial sanitaria, la pandemia por el COVID-19 que hasta la fecha va cobrando miles de vidas en la mayoría de los países. Desde mediados de Febrero del 2020 se ha venido estudiando el comportamiento epidemiológico y clínico de este virus, así como también se han dado propuestas de esquemas terapéuticos que aborden la eliminación del virus per se y sus complicaciones a nivel sistémico. Sin embargo, también se presentan síntomas neuropsiquiátricos en pacientes hospitalizados por esta infección, por lo que el manejo farmacológico requiere de consideraciones especiales al momento de su prescripción. A la fecha existe escasa bibliografía disponible sobre el uso potencial de fármacos psicotrópicos en pacientes infectados por COVID-19.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020; 25(3): 278-80.

Zhang L, Liu Y. Potential interventions for novel coronavirus in China: Uso de psicofármacos para síntomas neuropsiquiátricos en pacientes hospitalizados con COVID-19 a systematic review. J Med Virol. 2020; 92(5): 479-90.

Gobierno del Estado Peruano. Coronavirus en el Perú: casos confirmados [Internet]. Lima; 2020. Disponible en: https://www.gob.pe/

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178: 104787.

Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020; 35: 100684.

Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020; S0140-6736(20): 31180-6.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020; 323(18): 1824-36.

Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020; 55(5): 105955.

Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7(7): 611-27.

Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, et al. Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study. Brain Behav Immun. 2020; 88: 17-27.

Lovell N, Maddocks M, Etkind SN, Taylor K, Carey I, Vora V, et al. Characteristics, symptom management and outcomes of 101 patients with COVID-19 referred for hospital palliative care. J Pain Symptom Manage. 2020; S0885-3924(20): 30211-6.

Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav Immun. 2020; 88: 11-6.

Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011; 38(1): 10-20.

Harrold LR, John A, Reed GW, Haselkorn T, Karki C, Li Y, et al. Impact of Tocilizumab monotherapy on clinical and patient-reported quality of-life outcomes in patients with rheumatoid arthritis. Rheumatol Ther. 2017; 4(2): 405-17.

Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs. 2014; 28(2): 131-45.

Ginsberg DL. Azithromycin-induced psychotic depression and catatonia. Prim Psychiatry. 2006; 13(5): 22-6.

Dubovsky AN, Arvikar S, Stern TA, Axelrod L. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics. 2012; 53(2): 103-15.

National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement. Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ. 2020; 369: m1461.

Esteve Arríen A, Aguera Ortiz L, Manzano Palomo S. Manejo farmacológico de trastornos psicóticos en personas mayores con tratamiento de la infección por COVID19: interacciones y recomendaciones terapéuticas [Internet]. España; 2020. Disponible en:https://www.fesemi.org/sites/default/files/documentos/19.pdf

Khawam E, Khouli M, Pozuelo L. Treating acute anxiety in patients with Covid-19. Cleve Clin J Med. 2020.

University of Liverpool. Interactions with experimental COVID-19 Therapies [Internet]. 2020. Disponible en: https://www.covid19- druginteractions.org/

MedScape. Drug Interaction Checker [Internet]. 2020. Disponible en: https://reference.medscape.com/drug-interactionchecker

Huremović D. Psychiatry of Pandemics: a mental health response to infection outbreak. Springer Nature: Switzerland; 2019.

Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020; 250: 117583.

Zhang K, Zhou X, Liu H, Hashimoto K. Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders. Br J Psychiatry. 2020; 217(1): 351.

Lewis SR, Pritchard MW, Schofield-Robinson OJ, Alderson P, Smith AF. Melatonin for the promotion of sleep in adults in the intensive care unit. Cochrane Database Syst Rev. 2018; 5(5): CD012455.

Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001; 7(3): 249-64.

Luykx JJ, Van Veen SMP, Risselada A, Naarding P, Tijdink JK, Vinkers CH. Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic. Br J Psychiatry. 2020; 217(3): 471-4.

Livingston RL, Zucker DK, Isenberg K, Wetzel RD. Tricyclic antidepressants and delirium. J Clin Psychiatry. 1983; 44(5): 173-6.

Kotfis K, Williams-Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020; 24(1): 176.

Baller EB, Hogan CS, Fusunyan MA, Ivkovic A, Luccarelli JW, Madva E, et al. Neurocovid: pharmacological recommendations for delirium associated with COVID-19. Psychosomatics. 2020.

Manjunatha N, Naveen Kumar C, Bada Math S. Mental health in the times of COVID-19 pandemic: Guidance for general medical and specialised mental health care settings. National Department of Psychiatry National Institute of Mental Health & Neurosciences (NIMHANS). 2020.

Jernigan MG, Kipp GM, Rather A, Jenkins MT, Chung AM. Clinical implications and management of drug-drug interactions between antiretroviral agents and psychotropic medications. Ment Health Clin. 2013; 2(9): 274-85.

Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. Psychopharmacology of COVID-19. Psychosomatics. 202

##submission.downloads##

Publicado

2021-05-25

Cómo citar

Valdivieso Jimenez, G. (2021). Uso de psicofármacos para síntomas neuropsiquiátricos en pacientes hospitalizados con COVID-19 . Horizonte Médico (Lima), 21(2), e1272. https://doi.org/10.24265/horizmed.2021.v21n2.13

Número

Sección

Artículos de revisión